← Back to all signals
RESEARCH PAPER ANALYSIS

Gait asymmetry in Parkinson's disease - a systematic review and meta-analysis (AsymmGait-Parkinson study).

Systematic review and meta-analysis of 42 studies (2,111 pwPD) found greater gait asymmetry in Parkinson's disease—especially in step length, step time, and swing time—with swing time asymmetry most sensitive and partially responsive to dopaminergic medication.

PMID41942682
JournalScientific reports
Publication Date2026-04-07
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Systematic review and meta-analysis of 42 studies (2,111 pwPD) found greater gait asymmetry in Parkinson's disease—especially in step length, step time, and swing time—with swing time asymmetry most sensitive and partially responsive to dopaminergic medication.

WHY IT MATTERS

Research significance

Highlights swing time asymmetry as a measurable, treatment-responsive clinical biomarker that could improve phenotyping and outcome measures for trials and targeted gait interventions, though it offers limited mechanistic or direct therapeutic targets.

ABSTRACT

Source abstract

UNLABELLED: Gait asymmetry (GA) in people with Parkinson’s disease (pwPD) has been inconsistently reported, leading to uncertainty about its prevalence and clinical significance. GA may relate to motor symptoms’ lateralization and the effects of dopaminergic medication. The aim of this study was to systematically summarize the current literature and perform a meta-analysis to investigate the differences between GA in pwPD compared to healthy individuals and to evaluate the effect of dopaminergic medication on GA. The review was registered in PROSPERO database (ID: CRD42021285067). The searching was conducted in the PubMed, Cochrane Library, Lilacs, PEDro and Scopus databases. The primary search resulted in 551 studies. After removing the duplicates, 451 studies remained for the analysis. After checking the full text, 42 studies with 2111 pwPD were included in this review. The meta-analysis showed that pwPD exhibited greater asymmetry in step length, step time, and swing time, particularly in the OFF state, with moderate effect sizes. Dopaminergic medication was associated with reduced swing time asymmetry. Temporal aspects of GA, particularly swing time asymmetry, was most sensitive to detect differences in GA between pwPD and healthy controls and to indicate an effect of dopaminergic medication. The inconsistent findings across studies highlight the need for standardization in GA measurement. Understanding the neural mechanisms underlying GA may improve targeted therapies. Further research should explore GA in more challenging walking conditions and in free-living environments to enhance the clinical understanding of gait disturbances in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-026-46469-y.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic